Media Center
- No
-
Category
- Show all
- Press Release
- News Article
- PR Video
- CEO Story
- Title
- Author
- Time uploaded
- Views
- Likes
- 201
- Press Release
- Press Release PharmAbcine at JP Morgan Healthcare Conference 2025
- (주)파멥신
- 10 Jan 2025
- Views514
- 0
- 200
- Press Release
- Press Release PharmAbcine Announces Safety Approval for 3mg Multiple-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
- (주)파멥신
- 9 Jan 2025
- Views298
- 0
- 199
- Press Release
- Press Release PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
- PharmAbcine
- 16 Oct 2024
- Views1280
- 0
- 198
- Press Release
- Press Release PharmAbcine Announces Safety Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors
- PharmAbcine
- 9 Jul 2024
- Views2179
- 0
- 197
- Press Release
- Press Release PharmAbcine’s Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg
- PharmAbcine
- 2 Jul 2024
- Views2250
- 0
- 196
- Press Release
- Press Release PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024
- PharmAbcine
- 23 May 2024
- Views2648
- 0
- 195
- Press Release
- Press Release Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
- PharmAbcine
- 23 Apr 2024
- Views2930
- 0
- 194
- Press Release
- Press Release PharmAbcine Announces Japan Patent Registration for PMC-403
- PharmAbcine
- 29 Feb 2024
- Views2584
- 0
- 193
- Press Release
- Press Release PharmAbcine's PMC-403 Receives FDA Orphan Drug Designation for Idiopathic Systemic Capillary Leak Syndrome
- PharmAbcine
- 20 Feb 2024
- Views2155
- 0